These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6497944)

  • 1. Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
    Hanefeld M; Hora C; Schulze J; Rothe G; Barthel U; Haller H
    Atherosclerosis; 1984 Oct; 53(1):47-58. PubMed ID: 6497944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clofibrate therapy--the status quo].
    Reuter W
    Z Gesamte Inn Med; 1982 Jan; 37(2):59-63. PubMed ID: 7080553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of common lipoprotein disorders.
    Brown WV; Goldberg IJ; Ginsberg HN
    Prog Cardiovasc Dis; 1984; 27(1):1-20. PubMed ID: 6330792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemia and obesity 2011. Similarities and differences].
    Ceska R; Vrablík M; Sucharda P
    Vnitr Lek; 2011 Mar; 57(3):248-53. PubMed ID: 21495405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis of primary hyperlipoproteinemia during a preventive examination].
    Raslová K; Mongiellová V; Hucková M
    Cas Lek Cesk; 1993 Mar; 132(5):137-41. PubMed ID: 8472293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.
    Research Committee of the Scottish Society of Physicians
    Br Med J; 1971 Dec; 4(5790):775-84. PubMed ID: 4943606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperlipoproteinemias: significance--diagnosis--therapy].
    Schwandt P
    Internist (Berl); 1971 Nov; 12(11):481-7. PubMed ID: 4943880
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
    Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
    Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
    Julius U; Hora C; Gross P; Fücker K; Bergmann S; Hanefeld M
    Fortschr Med; 1992 Dec; 110(35-36):669-72. PubMed ID: 1487226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
    Hoeg JM; Maher MB; Bailey KR; Zech LA; Gregg RE; Sprecher DL; Brewer HB
    Am J Cardiol; 1985 May; 55(11):1282-6. PubMed ID: 3887883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current pharmacologic treatment of elevated serum cholesterol.
    Tikkanen MJ; Nikkilä EA
    Circulation; 1987 Sep; 76(3):529-33. PubMed ID: 3476221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic goals in hyperlipoproteinemia].
    Ceska R
    Vnitr Lek; 2000 Sep; 46(9):555-8. PubMed ID: 11344652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High lipid levels and coronary disease in women in Göteborg--outcome and secular trends: a prospective 19 year follow-up in the BEDA*study.
    Johansson S; Wilhelmsen L; Lappas G; Rosengren A
    Eur Heart J; 2003 Apr; 24(8):704-16. PubMed ID: 12713765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
    Steger W
    Fortschr Med; 1980 May; 98(18):(718-20). PubMed ID: 7390386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of hyperlipidemia and the role of probucol.
    Davignon J
    Am J Cardiol; 1986 Jun; 57(16):22H-28H. PubMed ID: 3460320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
    Padosh D; Kustosh D; Puchok I; Dem'ianova N; Audikovski M
    Klin Med (Mosk); 1981 Sep; 59(9):45-8. PubMed ID: 7311430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.